Pyrotinib in HER2-positive Early Breast Cancer
NCT06718335
·
clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
156
Enrollment
OTHER
Sponsor class
Conditions
HER2-positive Breast Cancer
Interventions
DRUG:
Pyrotinib
Sponsor
Nie Jianyun